CDKN2A (p16) mRNA decreased expression is a marker of poor prognosis in malignant high-grade glioma
- 242 Downloads
Human high-grade glioma is heterogeneous in nature based on pathological and genetic profiling. Various tumour suppressor gene alterations are considered as prognostic markers in high-grade glioma. Gene expression of CDKN2A (p16) is used in various cancers as a prognostic biomarker along with methylation and deletion status of this gene. Expression levels of p16 mRNA were not studied as a biomarker in gliomas before. In this study, we have performed mRNA quantification analysis on 48 high-grade glioma tissues and checked for a possible prognostic role. The decreased expression of p16 mRNA in majority of the tumour tissues (57.1 %) was observed when compared to control tissues (P = 0.02). mRNA expression level was correlated with clinical variables also. p16 deletion status and BMI1 mRNA expression were also considered for comparison. p16 mRNA was negatively correlated with the BMI1 mRNA (P = <0.0001) but not with p16 deletion. p16 mRNA expression, midline shift in MRI and tumour type were able to predict patient survival in overall survival (OS) and progression-free survival (PFS). p16 mRNA could independently predict prognosis of OS (P = 0.0146) and PFS (P = 0.0305) in multivariate analysis. We have shown that p16 mRNA expression can act as an independent prognostic biomarker in high-grade glioma.
KeywordsGlioma p16 Gene expression Decreased expression
Mr. Sibin M K is a CSIR-Senior Research Fellow; thus, financial support provided by CSIR, New Delhi, is kindly acknowledged. This study was financially supported by DST-SERB, Government of India. Histopathological diagnosis was done by the neuropathology department, NIMHANS duly acknowledged.
Conflicts of interest
- 8.Agarwal P, Kabir FML, DeInnocentes P, Bird RC. Tumor suppressor gene p16/INK4A/P16 and its role in cell cycle exit, differentiation, and determination of cell fate. Tumor suppressor genes. Rijeka, Croatia: InTech Open Access Pub, 1–34; 2012.Google Scholar
- 15.Sibin MK, Bhat DI, Lavanya C, Arati S, Chetan GK. Over-expression and lack of copy number variation in BMI-1 gene in human glioma from Indian population. Oncology Letters. 2015;(In Press).Google Scholar
- 31.Dong Y, Walsh MD, McGuckin MA, Gabrielli BG, Cummings MC, Wright RG, et al. Increased expression of cyclin-dependent kinase inhibitor 2 (P16) gene product P16INK4A in ovarian cancer is associated with progression and unfavourable prognosis. Int J Cancer. 1997;74(1):57–63.CrossRefPubMedGoogle Scholar
- 39.Farivar S, Zati Keikha R, Shiari R, Jadali F. Expression of bmi-1 in pediatric brain tumors as a new independent prognostic marker of patient survival. BioMed Research International, 2013; 2013.Google Scholar